financial guidance

The company's biggest revenue increase this quarter came from its diagnostics and genomics group, though its other businesses also posted increases.

The company said revenues from its non-invasive heart transplant rejection test AlloMap rose about 16 percent year over year.

The company also launched a clinical genomics service, offering newborn screening and high-throughput NSG for rare inherited diseases.

The company missed analyst estimates on its top line, but beat analyst estimates for adjusted earnings per share and raised its adjusted EPS guidance for FY 2017.

The company credited its molecular diagnostics and international businesses as drivers of new growth.

Qiagen's revenues grew 6 percent at constant exchange rates to $349.0 million, besting the average Wall Street estimate of $346.6 million.

The company, which beat analyst estimates on both the top and bottom lines, said completed Cologuard test volume rose 149 percent to 135,000 tests.

The change comes amid lower than expected revenues for the first half of this year, as well as an anticipated continued lack of reimbursement coverage in the US. 

The firm said today that it received a notice that it is out of compliance with a rule requiring timely filings with the US Securities and Exchange Commission.